Cargando…

Experience and Expectations of Ovarian Cancer Patients in Australia

Some of the most significant advances in ovarian cancer treatment have been those that result in improvements in progression-free survival (PFS); however there is little research to understand the value that patients place on accessing therapies that result in PFS as a clinical outcome related to su...

Descripción completa

Detalles Bibliográficos
Autores principales: Holliday, Catherine M., Morte, Maria, Byrne, Josephine M., Holliday, Anne T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863331/
https://www.ncbi.nlm.nih.gov/pubmed/29707001
http://dx.doi.org/10.1155/2018/7863520
_version_ 1783308364703334400
author Holliday, Catherine M.
Morte, Maria
Byrne, Josephine M.
Holliday, Anne T.
author_facet Holliday, Catherine M.
Morte, Maria
Byrne, Josephine M.
Holliday, Anne T.
author_sort Holliday, Catherine M.
collection PubMed
description Some of the most significant advances in ovarian cancer treatment have been those that result in improvements in progression-free survival (PFS); however there is little research to understand the value that patients place on accessing therapies that result in PFS as a clinical outcome related to survivorship. This study therefore aimed to understand the experience and expectations of women with ovarian cancer in Australia in relation to quality of life (QoL) and treatment options. An online survey collected demographic information and 13 investigator-derived structured interview questions were developed to understand the experience of women with ovarian cancer, their understanding of terminology associated with their condition, and expectations of future treatment. This study demonstrated that ovarian cancer patients equate PFS with being in remission and that patients expect QoL during that time to be good to excellent. Women in this study described excellent QoL as feeling positive and happy and not worrying about cancer, feeling fit and healthy without side effects, and being able to live life as they did before their diagnosis, including the absence of fear of progression or recurrence. It is therefore suggested that there is a positive relationship between PFS and QoL. While it is difficult to quantify QoL and further research is needed, the results of this study suggest that the minimum time that women with ovarian cancer expect in relation to treatments that result in PFS is approximately six months. In the absence of this information, decision-makers are left to make assumptions about the value women place on access to therapeutics that increase PFS, which for this type of cancer is an important aspect of survivorship.
format Online
Article
Text
id pubmed-5863331
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-58633312018-04-29 Experience and Expectations of Ovarian Cancer Patients in Australia Holliday, Catherine M. Morte, Maria Byrne, Josephine M. Holliday, Anne T. J Oncol Research Article Some of the most significant advances in ovarian cancer treatment have been those that result in improvements in progression-free survival (PFS); however there is little research to understand the value that patients place on accessing therapies that result in PFS as a clinical outcome related to survivorship. This study therefore aimed to understand the experience and expectations of women with ovarian cancer in Australia in relation to quality of life (QoL) and treatment options. An online survey collected demographic information and 13 investigator-derived structured interview questions were developed to understand the experience of women with ovarian cancer, their understanding of terminology associated with their condition, and expectations of future treatment. This study demonstrated that ovarian cancer patients equate PFS with being in remission and that patients expect QoL during that time to be good to excellent. Women in this study described excellent QoL as feeling positive and happy and not worrying about cancer, feeling fit and healthy without side effects, and being able to live life as they did before their diagnosis, including the absence of fear of progression or recurrence. It is therefore suggested that there is a positive relationship between PFS and QoL. While it is difficult to quantify QoL and further research is needed, the results of this study suggest that the minimum time that women with ovarian cancer expect in relation to treatments that result in PFS is approximately six months. In the absence of this information, decision-makers are left to make assumptions about the value women place on access to therapeutics that increase PFS, which for this type of cancer is an important aspect of survivorship. Hindawi 2018-03-07 /pmc/articles/PMC5863331/ /pubmed/29707001 http://dx.doi.org/10.1155/2018/7863520 Text en Copyright © 2018 Catherine M. Holliday et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Holliday, Catherine M.
Morte, Maria
Byrne, Josephine M.
Holliday, Anne T.
Experience and Expectations of Ovarian Cancer Patients in Australia
title Experience and Expectations of Ovarian Cancer Patients in Australia
title_full Experience and Expectations of Ovarian Cancer Patients in Australia
title_fullStr Experience and Expectations of Ovarian Cancer Patients in Australia
title_full_unstemmed Experience and Expectations of Ovarian Cancer Patients in Australia
title_short Experience and Expectations of Ovarian Cancer Patients in Australia
title_sort experience and expectations of ovarian cancer patients in australia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863331/
https://www.ncbi.nlm.nih.gov/pubmed/29707001
http://dx.doi.org/10.1155/2018/7863520
work_keys_str_mv AT hollidaycatherinem experienceandexpectationsofovariancancerpatientsinaustralia
AT mortemaria experienceandexpectationsofovariancancerpatientsinaustralia
AT byrnejosephinem experienceandexpectationsofovariancancerpatientsinaustralia
AT hollidayannet experienceandexpectationsofovariancancerpatientsinaustralia